F3 and prostate cancer: Given that androgen receptor dampens tissue factor, a pivotal mediator of coagulation and VTEs, expression via nuclear factor-kappa B (NF-κB) and early growth response protein 1, increased tissue factor expression is expected in androgen-deprived prostate cancer patients (27).